Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis

(2011) JH Krege et al.   BONE

Femoral strength in osteoporotic women treated with teriparatide or alendronate

(2011) Tony M. Keaveny et al.   BONE

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

(2011) F Jakob et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Association of hip strength estimates by finite-element analysis with fractures in women and men

(2011) Shreyasee Amin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans

(2011) Xiang Wang et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans

(2010) Tony M. Keaveny   Annals of the New York Academy of Sciences

Relation of vertebral deformities to bone density, structure, and strength

(2010) L Joseph Melton III et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment

(2009) Sven Prevrhal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study

(2009) Jan Borggrefe et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

(2009) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans

(2008) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment

(2008) Barbara M Obermayer-Pietsch et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Finite Element Analysis of the Proximal Femur and Hip Fracture Risk in Older Men

(2008) Eric S Orwoll et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

(2008) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis

(2008) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate

(2008) R. A. Wermers et al.   OSTEOPOROSIS INTERNATIONAL

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM